Bone morphogenetic protein 3B (BMP3B) is a member of the TGF-b superfamily. The BMP3B promoter sequence was previously identified as a target for aberrant DNA methylation in non-small-cell lung cancer (NSCLC). Aberrant DNA hypermethylation in the BMP3B promoter is associated with downregulation of BMP3B transcription in both primary human lung cancers as well as lung cancer cell lines. In order to understand the mechanisms of BMP3B silencing in lung cancer, a sample set of 91 primary NSCLCs was used to detect aberrant BMP3B promoter methylation, mutations in the coding sequence of BMP3B, and loss of heterozygosity (LOH). Our results showed that 45 of 91 (or 49.5%) tested primary NSCLCs exhibited increased promoter methylation, and 40% demonstrated LOH in at least one of the flanking microsatellite markers sJRH and D10S196 (63 kb upstream or 3.338 Mbp downstream of BMP3B). The lung cancer cell line A549, a type II alveolar epithelial human lung cancer cell line, is characterized by aberrant DNA promoter methylation. We used retroviral vector constructs containing the BMP3B cDNA to re-express the gene in A549 cells and to investigate the effects on cell growth. No change in the cell growth rate was observed after BMP3B re-expression, as compared to the vector controls. Although the number of colonies formed in anchorage-dependent assays was only slightly decreased, the colony-forming ability of A549 cells after BMP3B expression in anchorage-independent assays in soft agar was significantly reduced to 10% (Po0.005, t-test). Moreover, the in vivo tumorigenicity assay in nude mice indicated that cells re-expressing BMP3B grew significantly slower than cells not expressing BMP3B (Po0.05, t-test). In conclusion, this study provides evidence that BMP3B expression is repressed by different mechanisms in lung cancer, and that the silencing of BMP3B promotes lung tumor development.
Bone morphogenetic protein 3B (BMP3B) is a member of the TGF-b superfamily. The BMP3B promoter sequence was previously identified as a target for aberrant DNA methylation in non-small-cell lung cancer (NSCLC). Aberrant DNA hypermethylation in the BMP3B promoter is associated with downregulation of BMP3B transcription in both primary human lung cancers as well as lung cancer cell lines. In order to understand the mechanisms of BMP3B silencing in lung cancer, a sample set of 91 primary NSCLCs was used to detect aberrant BMP3B promoter methylation, mutations in the coding sequence of BMP3B, and loss of heterozygosity (LOH). Our results showed that 45 of 91 (or 49.5%) tested primary NSCLCs exhibited increased promoter methylation, and 40% demonstrated LOH in at least one of the flanking microsatellite markers sJRH and D10S196 (63 kb upstream or 3.338 Mbp downstream of BMP3B). The lung cancer cell line A549, a type II alveolar epithelial human lung cancer cell line, is characterized by aberrant DNA promoter methylation. We used retroviral vector constructs containing the BMP3B cDNA to re-express the gene in A549 cells and to investigate the effects on cell growth. No change in the cell growth rate was observed after BMP3B re-expression, as compared to the vector controls. Although the number of colonies formed in anchorage-dependent assays was only slightly decreased, the colony-forming ability of A549 cells after BMP3B expression in anchorage-independent assays in soft agar was significantly reduced to 10% (Po0.005, . Moreover, the in vivo tumorigenicity assay in nude mice indicated that cells re-expressing BMP3B grew significantly slower than cells not expressing BMP3B (Po0.05, t-test). In conclusion, this study provides evidence that BMP3B expression is repressed by different mechanisms Introduction DNA methylation of CpG islands in the promoter regions of genes has been correlated with silencing of tumor suppressor genes (Baylin et al., 1998; Plass and Soloway, 2002; Smiraglia and Plass, 2002) . Genome scans for aberrant DNA methylation have shown that up to 10% of CpG islands can be methylated in human malignancies (Costello et al., 2000) . Silencing of genes by DNA hypermethylation can be the sole mechanism of gene inactivation, or can cooperate with genetic mechanisms (including large deletions or other intragenic mutations) to inactivate putative tumor suppressor genes in tumors. Aberrant promoter methylation constitutes an equal mechanism to gene silencing in tumor development. However, since DNA methylation is a reversible event, whereas genetic alterations are not, there might be fundamental differences in those genes that are silenced primarily or exclusively by genetic events compared with those that are silenced principally by DNA methylation. Only a small number of genes that are predominantly inactivated by promoter methylation have been identified thus far. These genes were either identified in a candidate cancer gene approach, or in genome scans using AP-PCR (Liang et al., 2002) , MDA (Toyota and Issa, 2002) or restriction landmark genomic scanning (RLGS) (Costello et al., 2000) . Examples include GSTP1 in prostate cancer (Lee et al., 1994) , PAX6 (Liang et al., 2002) and Versican (Toyota et al., 1999) . RASSF1A is a lung tumor suppressor gene that was identified based on aberrant promoter DNA methylation and its location in a region of frequent loss of heterozygosity (LOH) in lung cancer (Dammann et al., 2000) .
Bone morphogenetic protein 3B (BMP3B) was identified in an RLGS scan for aberrant DNA methylation (Dai et al., 2001) . BMP3B is highly expressed in normal human lung (Hino et al., 1996) , but was found to be downregulated in primary non-small-cell lung cancers (NSCLCs) and cell lines (Dai et al., 2001) . After treating non-small-cell cancer cell lines with 5-aza-2 0 -deoxycytidine, a DNA methyltransferase inhibitor, the gene was re-expressed (Dai et al., 2001) , suggesting that DNA methylation was one of the mechanisms leading to BMP3B gene downregulation in lung cancer. BMP3B belongs to the TGF-b superfamily with highest homology to BMP3. BMP3B encodes a 478-amino-acid precursor protein that is processed into the mature BMP3B protein of 110 amino acids by cleavage. BMP3B is expressed at high levels in the lung, brain, skeletal muscle, pancreas and testis (Hino et al., 1996) . Both TGF-b and BMP members signal through the SMAD signaling transduction pathway critical for normal lung development (Miyazono et al., 2001) . The function of BMP3B has not been well characterized. However, BMP3B showed 82% homology to BMP3, the closest family member of BMP3B (Hino et al., 1996) , at the amino-acid level. The role of TGF-b, and especially TGF-b1, has been extensively studied in tumorigenesis (Derynck et al., 2001) . Current understanding indicates that TGF-b may possess either growth-suppressing or growth-promoting activity, depending upon the cellular context (Massague et al., 2000; Derynck et al., 2001; Miyazono et al., 2001) . It is noteworthy that during the late stage of tumor development, TGF-b is frequently overexpressed in tumors compared to their normal counterparts and promotes tumor progression by several different mechanisms (Derynck et al., 2001; Akhurst, 2002) . Since an antagonistic mechanism has been described for BMP3 and TGF-b (Faucheux et al., 1997) , we decided to investigate the role of BMP3B in lung tumorigenesis in greater detail.
We investigated the mechanisms of BMP3B silencing and the contribution of BMB3B inactivation to lung tumorigenesis in a large sample set of primary NSCLCs. We screened for BMP3B promoter methylation, as well as genetic changes such as point mutations and LOH. The gene was also re-expressed in A549 non-small-cell cancer cell line to evaluate BMP3B function in carcinogenesis. The growth properties of the cells after BMP3B re-expression were evaluated in both in vitro and in vivo studies. Finally, possible BMP3B downstream target genes were analysed using microarray gene profiling.
Results

Promoter methylation of BMP3B
We previously identified BMP3B methylation in a screen for aberrant DNA methylation in NSCLCs (Dai et al., 2001) . In this study, we also showed that BMP3B is frequently downregulated in primary tumors relatively matching normal lung tissue (Dai et al., 2001) . In order to determine the frequency of aberrant DNA methylation in this gene, we studied the methylation pattern by bisulfite sequencing of the promoter sequence. Primary lung cancer DNAs were prescreened using the COBRA assay (data not shown). DNAs from patient Nos. 3 and 5 (PT3 and PT5), identified as methylated, and PT2, P14 and P19 (with no aberrant methylation) were used for bisulfite sequencing of the promoter region (Figure 1 ). PT3 and PT5 showed 62 and 73% methylation of the total CpG dinucleotides, respectively. In contrast, only 9 and 20%, respectively, were methylated in the normal adjacent controls ( Figure  1a and b) . PT2, PT14 and P19 showed methylation in less than 10% of the CpG dinucleotides ( Figure 1a and (Hino et al., 1996) . (b) Bisulfite sequencing of BMP3B promoter region containing 28 CpG dinucleotides for matched patient samples PT3 and PT5. Open circle: no methylation of cytosine in CpG dinucleotides. Filled circle: methylated cytosine in CpG dinucleotides. (c) Bisulfite sequencing of BMP3B promoter region for tumor samples PT2, PT14 and PT19 and lung cancer cell line A549. (d) Representative MS-PCR to detect methylation in primary non-small-lung cancer patients. Each sample was amplified using primers specifically for unmethylated sequences (U) and for the methylated sequences (M). UT: genomic DNA without bisulfite treatment; 50%: control DNA with 50% methylation; N: normal adjacent tissue; T: tumor BMP3B in non-small-cell lung cancer Z Dai et al c). In addition, the lung cancer cell line A549, used for the BMP3B re-expression studies described below, showed 50% methylation (Figure 1a-c) .
In order to detect BMP3B promoter methylation in a larger set of primary NSCLCs, methylation-specific PCR (MSP) was performed on 19 paired primary NSCLC samples and 72 unpaired NSCLC samples. MSP primers were designed based on the bisulfite sequencing data described above to ensure their ability to discriminate between normal and tumor tissue. We found that eight of 19 paired samples (Table 2) showed increased methylation in the tumor samples as compared to their normal adjacent lung tissue. A total of four normal adjacent tissue DNAs were positive for the MSP. These results were consistent with the bisulfite sequencing results described above. Representative examples are shown in Figure 1d . In addition, in a set of 72 NSCLC samples without paired adjacent normal lung tissue, 37 of 72 tumors showed methylation. For these 72 samples, methylation was scored when the ratio of methylated band to unmethylated band within a sample was greater than the ratio in the 1% artificially methylated control. The overall frequency of methylation in NSCLC was 45 out of 91, or 49.5%, with no significant trend to preferential methylation of any of the studied subtypes (Table 1) .
Genetic alterations in BMP3B
BMP3B was identified in a screen for aberrant DNA methylation in lung cancer. In order to determine whether genetic mechanisms participate in gene silencing, we performed a screen for LOH and for mutations in the coding region of BMP3B. BMP3B is located on chromosome 10q11.22 between markers D10S208 and D10S196 (3.38 Mbp proximal to D10S196). LOH data for chromosome 10 were obtained from 19 paired patient samples (Table 2 ). The highest incidence of LOH was 40% detected for marker D10S196. Six of 15 patients showed LOH for this marker. Direct sequencing of the BMP3B coding region was used to search for possible mutations. No mutations were detected in the coding region of 83 tumor samples in our study. However, we found a polymorphism in a region containing six CTG repeats (position 502-519 in the published cDNA, NCBI accession number NM_004962.2) in exon 1. In-frame heterozygous loss of one CTG repeat (data not shown) from one allele was identified in four of 83 primary NSCLC samples, but was also present in normal adjacent lung tissue. The shorter version of BMP3B results in the omission of a single leucine in the amino-acid sequence. The functional consequences of this single amino-acid deletion are undetermined at this point. The results of the LOH studies on the 19 paired primary lung cancer samples are Re-expression of BMP3B in A549 cell line using pBabe-puro-BMP3B
In order to test the effects of BMP3B re-expression in human NSCLC, the full-length BMP3B coding sequence was ligated into retrovirus expression vector pBabe-puro. We started from IMAGE cDNA No. 308743, which starts at position þ 186 of the coding sequence. The missing 5 0 -end of the BMP3B coding sequence was generated through RT-PCR from normal lung cDNA to create the full-length coding sequence, which was subsequently verified by sequencing. In addition, a c-MYC tag was successfully amplified and cloned into the 5 0 -end of the BMP3B cDNA. The construct was also sequenced to confirm that both the c-MYC tag and BMP3B were in the correct reading frame. We tested nine lung cancer cell lines (H23, H2009, H2172, H125, H522, H1155, H2086, A549, H1299) for endogenous BMP3B expression and found that none expressed BMP3B (Dai et al., 2001; Z Dai and C Plass, unpublished) . The decision was made to use A549 cells for the transfections. After infection of the A549 cell line with pBabe-puro, pBabe-puro-BMP3B or pBabe-puro-MYC-BMP3B retrovirus, the majority of the A549 cells survived for 5 days after puromycin selection (3 mg/ml), while the noninfected A549 cells died in less than 48 h. The infected cells were maintained in the culture media supplemented with 3 mg/ml puromycin for all assays. Re-expression of BMP3B was demonstrated by RT-PCR (Figure 2a) . BMP3B was not detectable in A549 cells infected with the vector, but was expressed in both pBabe-puro-MYC-BMP3B and pBabe-puro-BMP3B. The possibility of genomic DNA contamination in the mRNA was excluded as no RT-PCR product was detected in the (À) RT control ( Figure 2a ). In addition, expression at the protein level was confirmed using an anti-c-MYC monoclonal antibody for Western blotting (Figure 2b ). The c-MYC tag protein was detected only in the A549 cells transfected with pBabe-puro-MYC-BMP3B.
In vitro and in vivo growth assay of pBabe-BMP3B-infected A549 cell line No obvious morphologic or growth rate changes were observed between the vector control, pBabe-puro-MYC-BMP3B and pBabe-puro-BMP3B-transfected groups in vitro (data not shown). We found that the BMP3B-transfected groups had approximately 30% fewer cells than the vector control. The anchoragedependent colony formation assays, repeated five times, showed results consistent with growth curve assays. Again, the BMP3B-transfected groups had about 30% fewer cells than the vector control groups. There is a statistically significant difference between the vectorand pBabe-puro-MYC-BMP3B groups, as well as between vector-and pBabe-puro-BMP3B groups (Po0.05, t-test) (Figure 3a) . But no statistical significance was observed between pBabe-puro-MYC-BMP3B and pBabe-puro-BMP3B groups (Figure 3a) .
The number of colonies formed in anchorage-independent assay in soft agar was significantly decreased in the BMP3B-transfected A549 cells. Only 10% of colonies formed when BMP3B was expressed from both the pBabe-puro-MYC-BMP3B and pBabe-puro-BMP3B constructs (Figure 3b ). Statistical significance was observed between the vector group and pBabepuro-MYC-BMP3B, as well as between vector-and pBabe-puro-BMP3B groups (Po0.005, t-test) (Figure 3b ), but not between pBabe-puro-MYC-BMP3B and pBabe-puro-BMP3B groups (P40.1, t-test) (Figure 3b ). Similar results were observed in three independent experiments.
Using an in vivo subcutaneous cell growth assay in nude mice, we observed a statistically significant difference in the average tumor volume between the vector control group and the pBabe-puro-BMP3B group after 42 days (Po0.05, t-test) (Figure 3c ). The average tumor weight of the 10 tumors grown subcutaneously was 46% lower in the pBabe-puro-BMP3B group than in the vector control group. The t-test indicates that there is also a statistically significant difference between the vector control group and the pBabe-puro-MYC-BMP3B group (Po0.05) (data not shown).
Discussion
In the present study, we demonstrate that the CpG island containing the BMP3B promoter is hypermethylated in 49.5% of NSCLC primary tumors (n ¼ 91) as detected by MSP. The MSP assay was designed based on bisulfite sequencing and consistent with the bisulfite sequencing results. Although no mutation was found in the BMP3B coding sequence, the region might be affected by other genetic changes, such as mutations in the 5 0 and 3 0 UTRs. In addition, 40% of primary NSCLC in this study (n ¼ 19) showed LOH in marker D10S196. Previously published data show that D10S208/D10S196 was a region of frequent allelic loss (41%) in a study of 36 human lung cancer cell lines (Girard et al., 2000) . Therefore, it is clear that the BMP3B locus is affected by epigenetic and genetic changes, both leading to loss of function of the gene product. Furthermore, our study shows that BMP3B significantly represses anchorage-independent cell growth in soft agar. Although no growth rate change was observed in the growth curve assay, there were fewer cells that survived in the BMP3B re-expression experiment confirming the anchorage-dependent colony formation assay and the in vivo cell growth assay in nude mice.
BMP3B belongs to a large family of cytokines, including TGF-bs, activin and BMPs. TGF-b, the beststudied member of this gene family, has a wide variety of biological activities, including the promotion of mesenchymal to epithelial transition during embryogenesis, context-dependent cell growth inhibition or stimulation, extracellular matrix synthesis and roles in the immune response (Verrecchia and Mauviel, 2002) . These cytokines bind to different serine/threonine kinase receptors and transmit their intracellular signals through the phosphorylation of SMAD proteins and subsequent activation or silencing of target genes (Miyazono et al., 2001) . TGF-b is a potent growth inhibitor in epithelial cells mediating its effects by inducing CDK inhibitors p15INK4B and/or p21CIP1 (Hannon and Beach, 1994; Datto et al., 1995) . Tumor suppressor activity has been clearly demonstrated in Tgfb-1 null mice that demonstrate an increase in the rate of spontaneously occurring or chemically induced tumors (Tang et al., 1998) . Multiple human tumors show increased levels of TGFb, contradictory to its function as a tumor suppressor gene (Derynck et al., 1987) . It is now becoming clear that autocrine and paracrine effects of TGF-b on tumor cells as well as the microenvironment have both positive and negative effects on tumor development (Derynck et al., 2001) . TGF-b can induce an epithelial to mesenchymal transition in cultures of normal and transformed cells, a process critical for tumors with invasive phenotype (Caulin et al., 1995; Oft et al., 1996; Thiery, 2002) .
It has been shown in rat calvarial osteoblast primary culture that BMP3B is completely inhibited at the transcriptional level by TGF-b1, indicating that transcriptional repression of BMP3B by inhibitory transcription factors would be another mechanism that silences BMP3B. Overexpression of TGF-b1 in NSCLC compared to that of adjacent normal lung might play a role in BMP3B downregulation in NSCLC (Colasante et al., 1997) . Similarly, BMP3, the closest family member of BMP3B, has also been shown to exert an antagonistic role against TGF-b1 in human bone marrow stoma during cell growth and differentiation (Faucheux et al., 1997) . Both findings suggest a tight regulation and well-balanced expression of both genes. Using microarrays containing 9000 cDNAs of gene sequences overexpressed in lung cancer, we detected no alteration of transcription of a gene higher than threefold. However, the three genes with the most pronounced decrease of expression are fibronectin transcript variant 1 (FN1), transforming growth factorb-induced, 68-kDa (TGFBI) and stearoyl-CoA desaturase (delta-9-desaturase) (SCD), showing 1.5-2-fold decrease of expression that was demonstrated consistently by multiple clones for each gene on the array. SYBR green semiquantitative PCR was performed to verify downregulation in these three genes (Plass et al., unpublished). Our expression data support this hypothesis, showing suppression of three genes that are known to be upregulated by TGF-b1: fibronectin, TGFBI and SCD. The left side bar graph shows the number of colonies formed after BMP3B re-expression compared to the vector control in three independent assays. Experiments were repeated three times (1st to 3rd). The 95% confidence intervals for each mean generated from triplicate experiments are shown as the error bar. The right side figure shows the colonies formed in soft agar. (c) In vivo cell growth assay in nude mice. The volume was calculated as width Â length Â height/2. In all, 10 mice were used for pBabe and pBabe-BMP3B groups, respectively BMP3B in non-small-cell lung cancer Z Dai et al been postulated that fibronectin promotes migration of cancer cells, an important step in epithelial to mesenchymal transition (Ridley, 2000) . In addition, fibronectin is upregulated during adenovirus E1A 12S mutant HBdl12-induced epithelial to mesenchymal transition in primary kidney cells (Kiemer et al., 2001) . TGFBI is a gene that was originally identified by differential hybridization as a target of TGF-b that could be induced up to 20-fold after 2 days of TGF-b treatment in A549 cells (Skonier et al., 1992) . Interestingly, TGFBI was also found to be overexpressed in lung cancer and was correlated with later stages of lung cancer (Sasaki et al., 2002) . SCD can be induced by TGF-b1, 2 or 3 in cultured human retinal pigment epithelial cells (Samuel et al., 2002) .
In conclusion, our study provides evidence of the tumor suppressor function of BMP3B in lung cancer. Our data, together with published data, suggest an antagonistic role of BMP3B and TGF-b to some degree. Silencing of BMP3B could shift lung cancer cells into an invasive stage by interrupting the equilibrium between BMP3B and TGF-b. This disruption would result in an excess of TGF-b that subsequently promotes tumor invasion and metastasis.
Materials and methods
Cell lines and primary lung cancer samples
Type II alveolar epithelial human lung cancer cell line A549 was cultured in RMPI-1640, supplemented with 10% fetal bovine serum, 100 U/ml penicillin and 0.1 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA). Cell lines transfected with the pBabe retrovirus were maintained in the same medium as the parental lines but the medium was supplemented with 3 mg/ ml puromycin. Phoenix amphotropic packaging cells were cultured in DMEM medium with 15% fetal bovine serum. In all, 19 paired primary NSCLC samples were collected by the Cooperative Human Tissue Network at The Ohio State University. In all, 72 additional primary lung cancer DNAs and four normal lung DNAs were collected at the Minneapolis, VA, Medical Center. All sample collection was performed according to NIH guidelines.
Bisulfite treatment of genomic DNA and sequencing
Bisulfite treatment of genomic DNA was performed with modifications using the previously published protocol (Herman et al., 1996) . Briefly, 1 mg genomic DNA was denatured by 3 M NaOH for 10 min at 371C in a volume of 50 ml and then incubated at 501C overnight following the addition of 10 ml 10 mM hydroquinone and 520 ml 3 M sodium bisulfite. The DNA was then purified using the Qiaquick gel extraction kit (Qiagen, Valencia, CA, USA) and eluted into 50 ml elution buffer. After adding 5 ml fresh 3 M NaOH, the reaction was incubated at room temperature for 5 min. A measure of 10 ml 3 M NaOAc (pH 5.0) was added to adjust the pH. The treated DNA was again purified using the Qiaquick gel extraction kit and eluted into 30 ml elution buffer. BMP3B bisulfite sequencing PCR primers were as follows: forward primer: 5 0 -TGTAGGGGTAATTTAGTAGGTAGG-3 0 and reverse primer: 5 0 -AACCTCTAAAACTACAACTAACAAAA-3 0 , located in the promoter region of BMP3B. A measure of 1 ml bisulfite converted DNA was amplified in a 50 ml volume for 951C for 10 min to activate Taq DNA polymerase, followed by 35 cycles of amplification (denaturing at 961C for 40 s, annealing at 581C for 1 min and extension at 721C for 66 s). The PCR product was gel purified using the Qiaquick gel extraction kit and cloned into the pCR2.1-TOPO vector (Invitrogen, Carlsbad, CA, USA). Single colonies were picked for plasmid DNA isolation using the QIAprep s Spin Miniprep kit (Qiagen) and subsequent sequence analysis.
Methylation-specific PCR analysis of BMP3B promoter
Methylation-specific PCR (MS-PCR) analysis was performed on bisulfite-treated DNA from 20 lung tumor samples paired with normal adjacent tissue and on an additional 72 lung tumor samples. Both the nonmethylation-specific primers (BMP3B-UF: 5 0 -TGGTGTTGATATATAGGAGTT-3 0 and BMP3B-UR: 5 0 -AAATCATCCCTAACCCAACT-3 0 ) and methylation-specific primers (BMP3B-MF: 5 0 -CGGCGTCGA-TATATAGGAGTC-3 0 and BMP3B-MR: 5 0 -AAATCGTC-CCTAACCCGACT-3 0 ) were designed to amplify a 166 bp region of the BMP3B promoter. Each amplification was performed in a 25 ml reaction. Nonmethylation-specific reactions were carried out for 38 cycles. For each cycle, the template was denatured at 961C for 30 s, primers were annealed at 561C for 15 s and the product was extended at 721C for 15 s. Methylation-specific reactions were carried out for 35 cycles. For each cycle, the template was denatured at 961C for 30 s, primers were annealed at 611C for 15 s and the product was extended at 721C for 15 s. Both reactions ended with a single extension at 721C for 7 min. As a control, '100%' methylated DNA was prepared from normal lung genomic DNA with M.SssI CpG methylase (New England BioLabs). M.SssI-treated DNA samples were purified using the QIAquick gel extraction kit (QIAGEN). In all, 0.1, 1, 10 and 50% methylated normal lung DNA were prepared by mixing M.SssI-methylated normal lung DNA and unmethylated normal lung DNA in 1 : 1000, 1 : 100, 1 : 10 and 1 : 1 ratios, respectively.
Mutation analysis
Mutation screening was carried out on 76 lung tumor DNA samples. Four different PCR amplification products were used to cover the coding regions of all three exons of BMP3B. The first 18 bases of the forward and reverse primers were 'tailed' with M13 forward and reverse primer sequences, respectively. PCR primer sequences are as follows: exon 1: BMP3Bmut1_F
0 . PCR amplification was performed in a 50 ml reaction containing B30 ng genomic DNA and 2.5 U of PfuTurbo hot start DNA polymerase (Stratagene), started at 951C for 2 min, then for 35 or 38 cycles of 30 s at 961C denaturation, 30 s at 601C annealing, 50 s at 721C extension. A 10 ml aliquot of each PCR amplification product was then subject to treatment with 10 U BMP3B in non-small-cell lung cancer Z Dai et al of exonuclease I (USB Corp., Cleveland, OH, USA) and 2 U of shrimp alkaline phosphatase (USB Corp.) for 15 min at 371C followed by 15 min at 801C to inactivate the enzymes. The PCR products were sequenced at the Genotyping-Sequencing Unit in the Division of Human Cancer Genetics, The Ohio State University. Differences were verified by sequencing from the reverse direction of reamplified PCR products.
Genotyping
Chromosome 10 markers, including D10S249, D10S591, D10-S189, D10S547, D10S1653, D10S548, D10S197, D10S208, D10S196, D10S1652, D10S537, D10S1686, D10S185, D10-S192, D10S597, D10S1693, D10S587, D10S217, D101651 and D10S212, were obtained from ABI's Linkage Mapping Set Version 2. The sJRH (GDB No. 273648) and GLUDP2.PCR primer sequences were obtained from the Genome Database, http://www.gdb.org. Primers were obtained from MWG Biotech Inc. Allelic ratios for normal/tumor pairs were calculated using the formula (height of normal allele 1/height of normal allele 2)/(height of tumor allele 1/height of tumor allele 2). A threshold of less than 0.67 or greater than 1.5 was determined as LOH.
Construction of the MYC-tagged pBabe-BMP3B expression vector
The IMAGE clone (No. 308743 in vector pT7T3D-Pac) containing the majority of the BMP3B cDNA was obtained from ATCC. This clone is lacking the 5 0 -end of the cDNA and starts at position þ 186 relative to the translation start site of the published coding sequence of BMP3B (NCBI accession number NM_004962.2). The BMP3B portion of the coding sequence missing at the 5 0 -end was amplified by RT-PCR from normal lung cDNA using forward primer 5 0 -AATCC-TAAGCTTCCTCCTCCTGGACTTCG-3 0 (AAGCTT is the HindIII restriction site) and reverse primer 5 0 -GAAATA-CACGGCCTTCTGGTCG-3 0 . The PCR product was digested by HindIII and SalI and ligated with the BMP3B image clone digested by the same enzymes. The HindIII site is located in the multiple cloning site of the vector and SalI is located in the BMP3B cDNA insert. Cloning of the full-length BMP3B coding region in pT7T3C-Pac was confirmed by sequencing. The full-length cDNA insert was cut out of the vector using HindIII and PmeI and subsequently ligated with the pcDNA3.1/hygro ( þ ) vector (Invitrogen), which was digested by HindIII and EcoRV (blunt end).
In order to prepare c-MYC-tagged BMP3B, the c-MYC tag sequence was prepared by PCR amplification from the pcDNA3-5 Â Myc plasmid. The forward primer used for this reaction was 5 0 -CCCAAGCTTGGATCCACCATGGA-3 0 and the reverse PCR primer was 5 0 -TACTAAGCTTTCCC-CAGATCCTCTT-3 0 . The PCR product contains a HindIII restriction site on each end of the c-MYC sequence. This HindIII fragment was cloned into the HindIII site of the pcDNA3.1/hygro-BMP3B plasmid. The c-MYC-tagged BMP3B was digested by BamHI and PmeI (blunt end) and was then ligated into the pBabe-puromycin vector digested by BamHI and SnaBI (blunt end). Using a similar strategy, pBabe-puro-BMP3B without the c-MYC tag was also constructed.
Retroviral infection of A549 cell line and puromycin selection
Plasmid DNA of the pBabe-vector, pBabe-puro-BMP3B and c-MYC-tagged pBabe-puro-BMP3B were transiently transfected into Phoenix amphotropic cells using calcium phosphate coprecipitation transfection. The retrovirus in the culture medium was harvested 48 h after transfection and then added to the A549 cell line at 30-40% confluency. This step was performed twice in a 12 h interval. At 36 h after infection, the A549 cells were split and cells containing the retrovirus were selected using 3 mg/ml puromycin medium for 5 days. Nontransfected A549 cells were used as controls for the selection and all cells died within 24-48 h.
RT-PCR
Total RNA from cell lines was isolated using TRIzol (Invitrogen) and further purified by the RNeasy Mini Kit (Qiagen). Total RNA (3 mg) was used for reverse transcription by both random hexamer and oligo dT using the SUPERSCRIPT TM First-Strand Synthesis kit (Invitrogen). Forward and reverse primers located at different exons were used to avoid amplification from genomic DNA (BMP3B forward: 5 0 -GGTGGACTTCGCAGACATCG-3 0 ; BMP3B reverse: 5 0 -GATGGTGGCATGGTTGGATG-3 0 ; product size: 130 bp. GPI forward: 5 0 -GACCCCCAGTTCCA-GAAGCTG-3 0 ; GPI reverse: 5 0 -GCATCACGTCCTCCGT-CACC-3 0 ; product size: 178 bp). Each PCR was performed in 50 ml final volume containing 1 ml cDNA from above, 1 Â PCR buffer, 1.5 mM MgCl 2 , 10 pmol of each primer, 200 mM of each dNTP and 2.5 U Platinum Taq DNA polymerase (Invitrogen). The PCR was performed in a Perkin-Elmer PCR 9700 machine (Perkin-Elmer Applied Biosystems, Foster City, CA, USA). The PCR started at 951C for 10 min to activate DNA polymerase. Both PCR reactions were carried out for 30-cycle amplification. For each cycle, the template was denatured at 961C for 25 s, annealed at 631C for 15 s and extended at 721C for 15 s.
SYBR green RT-PCR
cDNAs were prepared as described above. Primers were designed with Primer Express software (Applied Biosystems, Foster City, CA, USA), and the RT-PCR was performed with the GeneAmp 7000 Sequence Detection system (Applied Biosystems). The primer sequences are as follows: FN1-RT-F: TCCCTCGTGGCCATAAAGG; FN1-RT-R: GTGGAA-TAGAGCTCCCAGGCT (product size 85 bp); SCD-RT-F: CCACCTCTTCGGATATCGTCC; SCD-RT-R: CAGCGG-TACTCACTGGCAGA (product size 141 bp); TGFBI-RT-F: TCAAAGATGGAACCCCTCCA; TGFBI-RT-R: TGGT-TCCGAAGCAAATTCCTT (product size 55 bp); GPI-RT-F: CCCGAGTCCTCCCTGTTCAT; GPI-RT-R: TCGCCA-CTGCAGAAGGATC (product size 121 bp). The PCR was performed in a total volume of 25 ml, containing 1 Â SYBR green PCR Master mix (Applied Biosystems) and 7.5 pmol forward and reverse primers. The PCR was carried out for 40 cycles. For each cycle, the DNA was denatured at 951C for 15 s and annealed and extended at 601C for 1 min. Each sample was run in triplicate and the average was calculated.
Western blotting
We followed the previously published procedure with slight modification (Zhu et al., 2001a, b) . Cells were lysed with lysis buffer (50 mM Tris-HCl, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 0.1% Igepal CA-630 and protease inhibitor cocktail (Sigma)). Equal amounts of proteins (150-250 mg) were separated using 9% SDS-PAGE for detection of c-MYC via the 9E10 monoclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and of a-tubulin via the Ab-1 monoclonal antibody (Oncogene Research Products, Boston, MA, USA). Proteins on the gels were transferred onto Hybond TM ECL TM nitrocellulose membranes (Amersham BMP3B in non-small-cell lung cancer Z Dai et al Pharmacia Biotech, Uppsala, Sweden) and blocked in blocking buffer (5% nonfat milk, 200 mM NaCl, 25 mM Tris (pH 7.5) and 0.05% Tween 20). The blot was incubated with agitation with the primary antibody at 41C overnight. After washing once with TBS-T (20 mM Tris, 500 mM NaCl and 0.1% Tween 20), once with blocking buffer and four times with TBS-T (5 min each), membranes were incubated with the appropriate secondary antibody (anti-mouse 1 : 2000 for both c-MYC and a-tubulin antibody) at 41C for 1-2 h. After the same washing process used for the primary antibody, proteins were detected using a chemiluminescent detection system (Amersham Pharmacia Biotech).
Growth curve assay
In all, 10 000 cells from each cell line were seeded into 100-mm dishes. Each cell line was cultured in triplicate in RPMI 1640 medium containing 3 mg/ml puromycin. The cells were harvested and counted using a Coulter 
Anchorage-dependent colony formation assay
In all, 1000 cells were plated into 60-mm dishes. All cell lines were plated in triplicate. The cells were cultured for 14 days, washed twice with PBS, fixed with methanol/acetic acid (3 : 1), stained with 0.1% crystal violet in PBS for 30 min, washed and dried at room temperature.
Anchorage-independent colony formation assay in soft agar
Noble agar (Sigma) (4%) was prepared in H 2 O and autoclaved. The 4% agar was melted in the microwave and cooled to 501C in a waterbath. A measure of 5 ml of 4% agar was mixed with 35 ml medium (RMPI-1640, supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin and 3 mg/ml puromycin) prewarmed to 371C in a waterbath. A measure of 4 ml of the 0.5% agar in the medium was put into 60-mm dishes to provide the base agar. In the same way, 0.3% agar in the culture medium was prepared and cooled to 401C in a waterbath. In all, 2 Â 10 4 cells were suspended into 4 ml 0.3% agar for each 60-mm plate and plated on the base agar. All cell lines were plated in triplicate and experiments were repeated three times. After incubation at 371C for 14-21 days, the cell colonies were stained with 0.005% crystal violet for 1 h. The number of colonies was counted using a dissecting microscope.
In vivo cell growth assay in nude mice
Two million pBabe vector-or pBabe-BMP3B-infected cells in 0.5 ml culture medium (RMPI-1640, supplemented with 10% fetal bovine serum, 100 U/ml penicillin, 0.1 mg/ml streptomycin and 3 mg/ml puromycin) were subcutaneously injected into athymic-nu/nu nude mice (Charles River Laboratory, Wilmington, MA, USA). Tumors were measured weekly. The tumor volume was calculated as width Â length Â height/2. After 10 weeks, the mice were killed and the tumor weights were measured.
Statistic analysis of cell growth
The t-test was used to assess whether there are statistical differences in cell growth between the pBabe-puro vector control group, pBabe-puro-c-MYC-BMP3B group and pBabe-puro-BMP3B group.
Microarray study of pBabe vector-and pBabe-BMP3B-infected A549 9000 cDNA clones from subtractive RDA libraries (Hubank and Schatz, 1994) were used as probes. The common factor between these clones is that they are enriched for genes expressed at higher levels in tumors than in normal tissue. The libraries will be described in detail elsewhere (Amatschek et al., 2003, in press) . PCR products of these cDNAs were spotted onto poly-L-lysine-coated slides using the Promedia microarray printer (Promedia, Larchmont, NY, USA) and treated according to standard protocols available from http:// cmgm.stanford.edu/pbrown/protocols/ with minor variations. Briefly, DNA was covalently linked to poly-L-lysine by 60 mJ UV, and slides were blocked using succinic anhydride. In all, 20 mg total RNA from A549 cells transfected with a retrovirus expressing BMP3B as well as from control cells transfected with an empty virus was reverse transcribed in the presence of either Cy3-dUTP or Cy5-dUTP. After purification of labeled cDNAs by ethanol precipitation, a mixture of both labeled cDNAs was hybridized overnight onto the microarrays. In a dye-swap experiment, the labeling of RNAs was exchanged. After washing, independent images were obtained for Cy3 and Cy5 fluorescence emitted from hybridized microarrays by using the Affymetrix 428 dual channel laser scanner (Affymetrix, Santa Clara, CA, USA). The images were analysed with GenePix Pro software Version 4.0 (Axon Instruments, Foster City, CA, USA) and spots of poor quality, determined by visual inspection, were removed from further analysis. Net signal intensity (NSI) in each channel (Cy3 and Cy5) was determined by subtracting the local background from signal intensity values, and the median of ratios (mRs) of NSIs was used to determine the regulation of gene expression for each single probe. A correction for differences in overall intensities of both channels was applied via global normalization. This global normalization was carried out using the log of the median of all mRs, and is based on the assumption that the percentage of mRNA in the total RNA from both samples is identical.
Only features matching the following criteria were used for estimation of gene expression: (a) spots with X66% of feature pixels with intensities more than two standard deviations above the local background pixel intensities at both wavelengths. This parameter helps to eliminate features of low intensities that frequently can produce unreliable medians of ratios. (b) Spots with X0.5 Rgn R 2 , a parameter calculated by the GenePix Pro software that characterizes the coefficient of determination for the current regression value. Using this criterion, we have eliminated features of nonhomogeneous signals. (c) Spots with mR41.0 in one experiment and mRo1.0 in the dye-swap experiment or vice versa. This selection eliminates features showing a severe bias for Cy3 or Cy5 intensity.
